MedDeviceGuideMedDeviceGuide
Back
Labeling & UDIRegulatoryPolicy & LegislationUSEUMexicoChinaGlobal

UDI & Labeling Compared: FDA 801/830, EU MDR, Mexico NOM-137 & China

Legal-text comparison of medical device UDI and labeling: FDA 21 CFR Parts 801 & 830, EU MDR Article 27/Annex VI, Mexico NOM-137-SSA1-2025, and China Order 6/2014 — carriers, databases, and language.

Ran Chen
Ran Chen
Global MedTech Expert | 10× MedTech Global Access
Published 2026-06-16Last reviewed 2026-06-1611 min read

Four Labeling Regimes, One Identifier Concept — But Four Databases and Four Languages

A device's label has to carry the same core information everywhere — what it is, who made it, when it expires, which lot — but four legal texts turn that into four distinct obligations: the FDA's labeling and UDI rules (21 CFR Parts 801 and 830), the EU MDR's UDI and labeling provisions (Article 27 and Annex VI), Mexico's labeling standard (NOM-137-SSA1-2025), and China's instructions-and-labels provisions (CFDA Order 6/2014) plus the UDI Rules. They converge on the UDI-DI / UDI-PI structure and the existence of a central database, but diverge on which database, which language, direct-marking triggers, and compliance phasing.

This is a regulatory-research comparison for compliance planning, not labeling advice for a specific product. Verify every hook against the official text listed at the end.

Side-by-Side: Identifier, Carrier, Database, and Language

Dimension FDA (US) EU MDR Mexico (COFEPRIS) China (NMPA)
Legal text 21 CFR Parts 801 (labeling) & 830 (UDI) Regulation (EU) 2017/745, Art. 27–29 + Annex VI NOM-137-SSA1-2025 (effective May 14, 2027) CFDA Order 6/2014 (labels/IFU) + UDI Rules (NMPA, 2021)
Identifier structure UDI = DI + PI UDI = UDI-DI + UDI-PI; plus Basic UDI-DI for administration Sanitary-registration number + traceability elements (catalog, lot, serial) UDI = UDI-DI + UDI-PI; UDI-DI identifies registrant/filer + model + packaging
Carrier on label AIDC + HRI on label and package (§801.20) AIDC + HRI on label/device and all higher packaging (Annex VI C.4) Spanish text; may be supplemented by RFID/QR (must not contradict registration) Machine-readable + human-readable; Chinese language required
Direct marking Reusable/reprocessed devices (§801.45) Reusable devices — on the device itself (+2 yrs after label date) New: intended use, manufacturing date, catalog/model, single-use on label Per UDI Rules; carrier on device/package
Database GUDID (§830.300), submitted by the labeler EUDAMED UDI module (Art. 28); manufacturer submits/updates COFEPRIS sanitary-registration record (label design filed at registration) UDID (NMPA UDI database); UDI-DI + associated information
Issuing entity FDA-accredited issuing agencies (GS1, HIBCC, ICCBBA, IFA) Commission-designated issuing entities (GS1, HIBCC, IFA, ICGCMA) Domestic — COFEPRIS registration number is the key NMPA-recognized standards (e.g., GS1 China)
Compliance phasing Class III 2014 → Class II 2016 → Class I 2018 (direct mark 2022) Class III May 2021 → IIa/IIb May 2023 → Class I May 2025 One-year transition to May 14, 2027 Batch 1 (Class III) Jan 2021; Batch 2 June 2022; Batch 3 June 2024 (some Class II)

FDA: 21 CFR Parts 801 and 830 — The Original UDI Rule

The FDA's UDI system is the template the others reference, and it splits labeling rules (Part 801) from the identifier system (Part 830).

  • §801.20: the label of every device must bear a UDI, and every device package must bear a UDI meeting Part 830 — unless an exception/alternative applies.
  • §801.45 (direct marking): devices intended to be used more than once and reprocessed between uses must be directly marked with a UDI.
  • §801.18: certain dates on device labels must use a standardized format (year-month-day).
  • §830.20: the UDI comprises a device identifier (DI) (specific version/model + labeler) and a production identifier (PI) (lot/batch, serial, expiry, manufacture date, etc.).
  • §830.300: the labeler must submit the DI-referenced device attributes to the Global UDI Database (GUDID); the DI is the database key, the PI is not submitted to GUDID.
  • §830.40: UDI-DIs must be assigned by an FDA-accredited issuing agency (GS1, HIBCC, ICCBBA, IFA).
  • §801.30(a)(2) exception: a Class I device that the FDA has exempted from the QMSR (Part 820) GMP requirements is also exempt from UDI labeling — a US-only carve-out with no EU equivalent.

Cross-market trap: FDA compliance was phased by class over 2014–2022, with direct-marking enforcement discretion extended for some Class I devices to December 8, 2022. A labeler that grandfathered an older SKU under an enforcement-discretion policy in the US has no equivalent leniency in the EU (Class I labeling was required by 26 May 2025) or China (Class III since 2021) — the SKU is non-compliant there even if the US tolerates it.

Recommended Reading
FDA Emergency Use Authorization for Medical Devices: Regulatory Pathway
Regulatory 510(k)2026-04-17 · 15 min read

EU MDR: Article 27 and the Basic UDI-DI

The EU's system copies the DI/PI structure but adds a Basic UDI-DI that does not appear on the device and a more detailed EUDAMED data set.

  • Article 27: establishes the EU UDI system; manufacturers assign a UDI to the device and all higher levels of packaging before placing it on the market (custom-made and investigational devices exempt).
  • Article 28: establishes the UDI database (part of EUDAMED); Article 29 requires device registration.
  • Annex VI, Part C: the UDI carrier (both AIDC and HRI) goes on the label/device and all higher-level packaging (shipping containers excluded); for reusable devices, the carrier is placed on the device itself and the PI must remain readable after each reprocessing cycle.
  • Annex VI, Part C 4.4 (point-of-sale): for devices exclusively intended for retail point of sale, the UDI-PI in AIDC need not appear on the point-of-sale packaging — a narrow relief for consumer-facing products.
  • Basic UDI-DI: a master identifier used in the declaration of conformity, technical documentation, certificates of free sale, and EUDAMED registration — it is not printed on the device.
  • Phasing (Article 123(f)(g)): Class III UDI labeling by 26 May 2021; Class IIa/IIb by 26 May 2023; Class I by 26 May 2025; reusable-device direct marking two years after the relevant class's label date.

Cross-market trap: the EU requires more data elements in EUDAMED than GUDID does (e.g., single-use flag, sterile packaging flag, critical warnings such as latex/MRI/DEHP), and the Basic UDI-DI has no US equivalent. Firms that design a single master-data record for GUDID will need to extend it for EUDAMED, and a SKU's Basic UDI-DI must be consistent across the declaration of conformity and the registration or the conformity assessment stalls.

Mexico: NOM-137-SSA1-2025 — Spanish Labeling With New Traceability Hooks

Mexico's labeling standard was overhauled in 2026, replacing the 2008 version with a text that tightens traceability and language requirements.

  • NOM-137-SSA1-2025 was published May 19, 2026 and enters into force May 14, 2027 (a 360-day transition), repealing and replacing NOM-137-SSA1-2008. It aligns with FDA, EU MDR/IVDR, and IMDRF guidelines. A further 180-day sell-through window (180 días naturales) lets firms exhaust existing stocks of packaging materials and finished products that cannot be relabeled immediately — roughly through November 2027.
  • Language: all health information on labels and back-labels must be in Spanish, with legible typography; the device trade name may remain in its original language. When the original label lacks required elements (common with imports), a counter-label may be added after customs clearance and before marketing.
  • Mandatory identification elements: generic name (accepted by COFEPRIS), distinctive name (trademark), COFEPRIS sanitary-registration number, expiry date, manufacturing date, lot or serial number, catalog/model/version number, content, and full manufacturer/importer/distributor identification.
  • New vs 2008: the 2025 text adds intended use, manufacturing date, catalog/model number, a single-use indication, and adverse-incident instructions to the label; introduces definitions for "component" and "single-use device"; and permits supplementary information via RFID/QR provided it does not contradict the authorized registration.

Cross-market trap: Mexico's anchor identifier is the COFEPRIS sanitary-registration number, not a UDI-DI — there is no Mexican UDI mandate in this standard. A label built around a GS1 UDI for the US/EU must still add the Spanish-language block and the COFEPRIS registration number. Although May 14, 2027 is the entry-into-force date for all devices on the Mexican market, the standard's built-in 180-day sell-through window means legacy packaging and finished-product stock does not have to be pulled — but artwork for new and replenished stock must comply by May 2027, so the relabeling program has to land on that earlier clock.

China: Order 6/2014 (Labels/IFU) + the NMPA UDI Rules

China runs a labels-and-IFU regime (Order 6/2014) in parallel with a phased UDI regime (NMPA UDI Rules), both requiring Chinese-language information.

  • CFDA Order 6/2014 (Provisions for Instructions and Labels of Medical Devices), effective October 1, 2014: every device sold or used in China must be accompanied by instructions (IFU) and labels; instructions must accompany the minimal sale unit (Article 7); symbols must meet national standards or be explained in the IFU (Article 6). Underpinning authority is Article 39 of the State Council Regulation (Decree 739, 2021).
  • Label content (Article 13): product name, model/variant, manufacturer name/address/contact, NMPA certificate and product technical requirement (PTR) number, manufacturing date and validity/expiry — in Chinese where label space is limited (otherwise in the IFU).
  • NMPA UDI Rules (2021): the UDI system = UDI + UDI data carrier + UDI database (UDID); UDI comprises UDI-DI (registrant/filer + model/specification + packaging) and UDI-PI (serial, batch, production date, expiry). A new UDI-DI is required when a change affects identification, traceability, or regulatory requirements.
  • Phasing: Batch 1 (January 1, 2021) — selected Class III devices; Batch 2 (June 1, 2022) — further Class III devices including IVD reagents; Batch 3 (June 1, 2024) — selected Class II devices (including high-demand single-use and centralized-procurement items).

Cross-market trap: China's UDI-DI is tied to the registrant/filer and PTR, and the UDID is a separate NMPA database — a GS1 DI assigned for GUDID/EUDAMED must be reconciled with the NMPA registration and the Chinese-language label/IFU under Order 6/2014. Symbols acceptable in the US/EU without explanation may require IFU explanation in China if no equivalent national standard exists.

Recommended Reading
Investigational Device Rules Compared: FDA 21 CFR 812, EU MDR, SFDA & Health Canada
Clinical Evidence Regulatory2026-06-16 · 10 min read

What to Verify in the Original Text

  • 21 CFR 801.18, 801.20, 801.45 and 830.20, 830.40, 830.300: confirm the UDI-on-label/package rule, the direct-marking trigger for reusable devices, the DI/PI structure, the issuing-agency requirement, and the GUDID submission duty — then re-check the class-based compliance dates and any remaining enforcement-discretion windows.
  • EU MDR Article 27(3), 28, 29 and Annex VI Parts B and C: confirm the UDI-carrier placement rules, the Basic UDI-DI vs UDI-DI distinction, the extra EUDAMED data elements, and the Article 123(f)(g) phasing (Class I by 26 May 2025; reusable direct marking +2 years).
  • NOM-137-SSA1-2025 (effective May 14, 2027): confirm the Spanish-language rule, the mandatory identification elements (including the COFEPRIS registration number, manufacturing date, catalog number, intended use), the counter-label route for imports, and that there is no separate Mexican UDI mandate in this standard.
  • CFDA Order 6/2014, Articles 6, 7, 13, and the NMPA UDI Rules (2021): confirm the Chinese-language IFU/label duty, the NMPA certificate/PTR number on the label, the UDI-DI/UDI-PI structure, the UDID database, and the phased batch compliance dates (2021 / 2022 / 2024).

Practical Implications for a Global Labeling Program

For a device sold across all four markets, the UDI backbone (GS1 or another accredited issuing entity's DI/PI) is the unifying element, but each regime adds a layer that the others do not: the FDA wants GUDID submission keyed on the DI; the EU wants the Basic UDI-DI plus an expanded EUDAMED data set and reusable-device direct marking; Mexico wants Spanish labels with the COFEPRIS registration number and the new 2025 traceability elements by May 14, 2027; and China wants Chinese-language IFU/labels under Order 6/2014, the NMPA certificate/PTR on the label, and UDID submission on the phased batch schedule. The single biggest planning error is assuming one global GS1 label satisfies all four — it satisfies the carrier, but not the language, the registration number, the database, or the phased compliance date. Build a master-data model keyed on the UDI-DI with jurisdiction-specific overlays (EUDAMED extra fields, COFEPRIS number, NMPA PTR) and track the four separate compliance clocks — EU Class I (May 2025), Mexico NOM-137 (May 2027), China batch dates, and any remaining US direct-marking discretion — against the official texts before locking artwork.

Sources

Related Articles

Regulatory510(k)

FDA 510(k) Clearance Trends 1995-2026: Volume Stable as Traditional Submissions Take Share

Analysis of 175,149 FDA 510(k) clearances. Volume stabilized at roughly 3,200 per year after 2007, while Traditional submissions rose from 73% to 83% as Special and Abbreviated programs declined.

2026-06-16·10 min read
RegulatoryQuality Systems

FDA Medical Device Recall Concentration: Top 50 Firms Drive Over Half of All Recalls

Analysis of 58,374 FDA recall records: recall burden is concentrated. The top 50 firms drive 52% of recalls while 42% of firms recalled only once. Zimmer Biomet, Philips, Stryker, and Medtronic lead.

2026-06-16·11 min read
RegulatoryQuality Systems

FDA Orthopedic Implant Recalls: Zimmer Biomet Leads 3,167 Hip & Knee Recall Records

FDA recall analysis: 3,167 hip, knee, and shoulder joint-replacement recalls across 70 product codes. Zimmer Biomet holds 37%, the top-10 firms 87%, and 96% are Class II 510(k) devices, not PMA.

2026-06-16·10 min read